Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Sutro_Biopharma,_Inc.
|
| gptkbp:businessModel |
licensing agreements
collaborative research |
| gptkbp:CEO |
gptkb:Bill_Newell
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 autoimmune diseases innovative therapies cancer therapies biopharmaceutical company patient-centric approaches |
| gptkbp:collaborations |
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco multiple biopharma companies |
| gptkbp:employees |
over 100
|
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
2003
|
| gptkbp:founder |
gptkb:Bill_Newell
|
| gptkbp:funding |
venture capital
public offering |
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sutro Biopharma
|
| gptkbp:investmentFocus |
gptkb:Sofinnova_Ventures
gptkb:Canaan_Partners gptkb:MPM_Capital OrbiMed Advisors Foresite Capital |
| gptkbp:market |
biopharmaceuticals
therapeutic proteins |
| gptkbp:mission |
transforming lives through innovative therapies
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
academic institutions industry leaders Celgene |
| gptkbp:patentCitation |
biotechnology innovations
therapeutic methods |
| gptkbp:platforms |
molecular engineering
cell-free protein synthesis |
| gptkbp:publications |
peer-reviewed journals
conference presentations |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:research_areas |
oncology
immunology |
| gptkbp:research_focus |
biologics
antibody-drug conjugates |
| gptkbp:specialization |
protein engineering
|
| gptkbp:stockExchange |
gptkb:NASDAQ
STRO |
| gptkbp:supplyChain |
STRO-002
STRO-001 |
| gptkbp:technology |
XpressCF
XpressCF+_platform |
| gptkbp:tributaryOf |
multiple candidates
|
| gptkbp:vision |
leading in protein engineering
|
| gptkbp:website |
www.sutrobio.com
|